Drugs / Autologous Muscle Derived Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02463448 | Nov 2016 → Dec 2019 | — | Jason Gilleran | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01008943 | Jun 2010 → Sep 2012 | female stress incontinence | Cook MyoSite | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04661293 Background | — | — | Cook MyoSite | Temporarily not available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Muscle Derived Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02463448 ↗ |
| Known as | AMDCs | “Autologous Muscle Derived Cells (AMDCs)” NCT04661293 ↗ |
| Modality | Cell therapy | “Autologous Cell Therapy for Female Stress Urinary Incontinence” NCT01008943 ↗ |
| Route | Other | “Urethral injection of autologous muscle-derived cells” NCT01008943 ↗ |